Ted Jenkins
Senior Director, Investor Relations and Corporate Communications
Replay available
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) Q3 2020 earnings conference call, held 2020-11-10. Replay captured from the company's public earnings webcast.

Senior Director, Investor Relations and Corporate Communications
Chief Executive Officer
Chief Medical Officer and Head of Research
Analyst, RBC Capital Markets
Analyst, Jefferies (for Murray Raycroft)
Analyst, Oppenheimer
Hello and welcome to the Corbett Pharmaceuticals third quarter November 10th, 2020 earnings conference call. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during a conference, please press star zero on your telephone keypad. Following the presentation, there will be a question and answer session. Do note that this conference is being recorded at company's request and will be made available on the company's website following the end of the call. I will now turn the conference over to your host, Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Please go ahead, sir. Thank you, Operator, and good morning, everyone. Thank you for joining us today. At this time, I'd like to remind our listeners that remarks made during this call state management's intentions, hopes, beliefs, expectations, or projections of the future. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Security's laws. These forward-looking statements are based on Corpus' current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Corpus files with Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Joining me on the call today are Dr. Yuval Cohen, our Chief Ex...